Clinical trials
Carboplatin clinical trials
Below are recruiting carboplatin clinical trials, each written for real people, not researchers. We’re tracking 483 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06448754RecruitingPhase 2
Volrustomig for first-line advanced lung cancer
This trial tests a new drug called volrustomig, which helps your immune system fight cancer, as a first treatment for advanced non-small cell lung cancer. It's for people whose tumors do not have certain gene changes (like EGFR) that have other targeted treatments available.
Los Angeles, CaliforniaAges 18–130 - NCT06457503RecruitingPhase 4
Toripalimab plus chemo for advanced nasopharyngeal cancer
This trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy (cisplatin and gemcitabine) can help people whose nasopharyngeal cancer has come back or spread. It is for those who haven't yet received other treatments for this advanced stage.
Little Rock, ArkansasAges 12 years+ - NCT06463665RecruitingPhase 2
Virus therapy with chemo and immunotherapy for advanced lung cancer
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
Bullhead City, ArizonaAges 18 years+ - NCT06466382Recruiting
Personalized therapy for advanced ovarian cancer
This study tests a personalized cancer therapy designed just for you and your tumor. It is for people with newly diagnosed advanced ovarian cancer who can wait a short time before starting treatment and plan to have surgery after 2 cycles of chemotherapy.
Baden, Canton of AargauAges 18 years+ - NCT06467617RecruitingPhase 2
Immunotherapy and chemo before and after lung cancer surgery
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT06480864Recruiting
Study of adebelimumab and apatinib for extensive stage small cell lung cancer maintenance
This trial tests whether adding two targeted therapies (adebelimumab, an immunotherapy, and apatinib, a drug that blocks blood vessel growth) after initial chemotherapy can help keep extensive stage small cell lung cancer under control. It is for people who have not yet had systemic treatment for their cancer and are in good enough health to try this maintenance approach.
Shenyang, LiaoningAges 18 years+ - NCT06484491Recruiting
Higher-dose proton therapy for stage III lung cancer
This trial tests whether giving a higher dose of a special, precise form of radiation (proton therapy) to the main tumor can improve outcomes for people with stage III lung cancer who are already scheduled for chemoradiation and immunotherapy. It may help by targeting the tumor more effectively while protecting nearby organs.
GroningenAges 18 years+ - NCT06532149Recruiting
Sexual health and erectile function in men with lung cancer
This study looks at how lung cancer and its treatments affect men's sexual health, including erectile function and hormone levels. If you are a man with advanced lung cancer and are sexually active, researchers want to learn about your experiences and test results.
RomeAges 18–75 - NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
Denver, ColoradoAges 18 years+ - NCT07601737RecruitingPhase 2
Nimotuzumab with immunotherapy and chemotherapy for head and neck cancer
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
ShanghaiAges 18–75 - NCT06492759RecruitingPhase 2
High-dose radiation with pembrolizumab and chemo for pd-l1 positive tnbc
This trial tests giving high-dose radiation along with the immunotherapy drug pembrolizumab and chemo to people with a specific subtype of advanced breast cancer (PD-L1 positive triple negative). It may help shrink tumors and keep them from growing.
Atlanta, GeorgiaAges 18 years+ - NCT06497530RecruitingPhase 2
Lurbinectedin with serplulimab for extensive-stage SCLC maintenance
This trial tests a combination of two drugs, lurbinectedin and serplulimab, as maintenance therapy after initial chemotherapy for people with extensive-stage small cell lung cancer (SCLC) that hasn't spread to the brain. The goal is to see if this approach helps keep the cancer from growing for longer.
Guangzhou, GuangdongAges 18 years+ - NCT06502743RecruitingPhase 2
Study of chemotherapy and pembrolizumab with or without nesuparib for endometrial cancer
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
Kyeonggi-doAges 19 years+ - NCT06512051RecruitingPhase 1/Phase 2
Study of SHR-A2102 and Adebrelimab for advanced lung cancer
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, with or without other treatments, for people with advanced or metastatic non-small cell lung cancer that cannot be removed by surgery or cured with radiation. It aims to see if this approach can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–70 - NCT06522828RecruitingPhase 2
Study of SSGJ-707 for advanced gynecologic cancers
This trial tests a new drug called SSGJ-707 for people with advanced endometrial cancer or ovarian cancer that no longer responds to platinum-based chemotherapy. The goal is to see if it can help shrink or slow down the cancer.
ChongqingAges 18–75 - NCT06528691RecruitingPhase 2
Entrectinib for young children with NTRK/ROS1 brain tumors
This trial tests a targeted drug (entrectinib) in very young children (under 3) with a newly diagnosed brain tumor that has a specific genetic change (NTRK or ROS1 fusion). The drug works by blocking signals that help the tumor grow, and is given as the first treatment, before any chemotherapy or radiation.
Memphis, TennesseeAges Up to 3 years - NCT06536868RecruitingPhase 2
Tislelizumab with chemo and radiation for extensive-stage small cell lung cancer
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and chest radiation for people with extensive-stage small cell lung cancer (SCLC) that has spread. The goal is to see if this combination helps shrink or control the cancer longer.
Jincheng, ShanxiAges 18–80 - NCT06551142RecruitingPhase 1
Study of GSK5764227 for advanced solid tumors
This study tests a new drug called GSK5764227 for people with advanced solid tumors. It aims to see if the drug is safe and works against cancer that has stopped responding to other treatments.
Stanford, CaliforniaAges 18 years+ - NCT06561386RecruitingPhase 3
Testing a new drug combo for advanced lung cancer
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Mobile, AlabamaAges 18 years+ - NCT06561685RecruitingPhase 1
Study of LY4050784 for Advanced Solid Tumors with SMARCA4 Changes
This trial tests a new drug, LY4050784, for people with advanced solid tumors that have a specific change in a gene called SMARCA4 (BRG1). The study aims to see if the drug is safe and effective. It may be an option for those who have tried other treatments or have no standard options left.
Santa Monica, CaliforniaAges 18 years+ - NCT06576973RecruitingPhase 2
Adalimumab combo therapy for esophageal cancer before surgery
This trial tests a combination of an immunotherapy drug (adalimumab), chemotherapy, and a targeted therapy pill (apatinib) before surgery for esophageal cancer that can be removed. The goal is to see if this mix helps shrink the tumor and improve outcomes.
Hangzhou, ChinaAges 18–75 - NCT06659042RecruitingPhase 2
Tislelizumab before and after surgery for KRAS-mutated lung cancer
This trial tests whether adding the immunotherapy drug tislelizumab before and after surgery can help people with a specific type of lung cancer (non-squamous NSCLC with a KRAS mutation) that is stage 2 or 3. It aims to improve treatment outcomes by targeting the cancer early.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06663098RecruitingPhase 2
Atezolizumab and chemo again for relapsed small cell lung cancer
This trial tests a combination of a second course of chemotherapy and an immunotherapy drug (atezolizumab) for people with extensive-stage small cell lung cancer that has returned after initial treatment. The goal is to see if re-using these treatments together can help control the cancer again.
Aviano (PN)Ages 18 years+ - NCT06667167RecruitingPhase 2
First-line Keytruda + chemo then Keytruda + Trodelvy for SCLC
This trial tests a two-step treatment for extensive-stage small cell lung cancer: first, chemotherapy combined with Keytruda (an immunotherapy), followed by Keytruda plus Trodelvy (another targeted drug). The goal is to see if this combination helps people live longer and keeps the cancer under control.
Jerusalem, IsraelAges 18–99
Hear when a new Carboplatin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carboplatin?
- Yes. Clin2 currently lists 483 recruiting carboplatin studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carboplatin trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carboplatin trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.